10 citations
,
August 2022 in “JAAD Case Reports” Oral tofacitinib effectively regrows hair in children with alopecia areata without major side effects.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
May 2024 in “Pigment International” Several treatments are effective for pigmentary disorders like vitiligo and melasma.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
July 2024 in “Journal of Investigative Dermatology” February 2026 in “Figshare” February 2026 in “Figshare”
40 citations
,
April 2014 in “Genes & Development” Hormones during pregnancy and lactation keep skin stem cells inactive, preventing hair growth.
63 citations
,
April 2005 in “Mechanisms of development” Mice with too much Claudin-6 have skin barrier problems and abnormal hair growth.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
30 citations
,
October 1999 in “Differentiation” Mutant MK6a transgenes in mice cause blistering, hair loss, and potential human alopecia.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
April 2016 in “Journal of Investigative Dermatology” Blocking certain proteins can significantly regrow hair in severe alopecia areata.
90 citations
,
February 2001 in “The journal of investigative dermatology/Journal of investigative dermatology” Interleukin-1 increases keratin K6 production in skin cells.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” MPZL3 protein helps keep sebaceous gland size and cell growth in check.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
179 citations
,
May 1982 in “The Journal of clinical investigation/The journal of clinical investigation” High levels of 3 alpha-diol glucuronide in the blood are a marker of increased androgen action in women with excessive hair growth of unknown cause.
The document's conclusion cannot be provided because the document is not available or cannot be read.
21 citations
,
September 2019 in “Journal of the American Academy of Dermatology” Ixekizumab effectively treats generalized pustular psoriasis.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
November 2025 in “Journal of Dermatological Treatment” Dexamethasone oral mini-pulse therapy effectively treats severe alopecia areata when JAK inhibitors can't be used.
December 2024 in “Drug Discoveries & Therapeutics” Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.